West Completes $80 Million Manufacturing Expansion to Support Diabetes and Obesity Treatments for Patients Worldwide

West Pharmaceutical Services, Inc. announces the completion of an $80 million capacity expansion at its Contract Manufacturing site in Grand Rapids, Michigan

EXTON, PA August 21, 2024 – West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, recently announced it has completed an $80 million capacity expansion at its Contract Manufacturing site in Grand Rapids, Michigan. This investment will extend production and accessibility for patient-centric diabetes and obesity products, in response to increasing demand from West’s customers for device and drug delivery manufacturing solutions to support chronic disease treatments.

“West is proud to continue to support our customers in addressing the ever-changing landscape of healthcare. With a growing obesity and diabetes epidemic, this expansion will further support our customers’ device manufacturing requirements, helping to ensure reliable supply for these critical treatments today and in the future,” Aileen Ruff, President, Contract Manufacturing at West, stated.

As the needs of healthcare are evolving for more patient-focused drug delivery solutions, access to development and commercialization services to help bring these products to market becomes increasingly critical. West has invested globally to support these drug delivery requirements, and this most recent manufacturing investment in Grand Rapids reflects West’s strategy of meeting its customers’ growing needs with both product and service offerings.

Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as “extend,” “ensure,” and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. Specifically, there is no certainty that expansion at its Contract Manufacturing site in Grand Rapids, Michigan will achieve any particular result. These forward-looking statements involve a number of risks and uncertainties. Various factors could cause the actual results to differ materially from those expressed in, or underlying, these forward-looking statements, such as customers’ changing inventory requirements and manufacturing plans; customer decisions to move forward with new products and product categories; dependence on third party suppliers and partners; interruptions or weaknesses in the supply chain; and increased raw material costs. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2023. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West

West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year.

Headquartered in Exton, Pennsylvania, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.